Management of Voiding Problems in Older Men. Dr. John Fenn Consultant, QEH 10 th October, 2005
|
|
- Miles Rogers
- 5 years ago
- Views:
Transcription
1 Management of Voiding Problems in Older Men Dr. John Fenn Consultant, QEH 10 th October, 2005
2 Voiding Problems Poor stream Hesitancy Straining Incomplete emptying Intermittent micturition Terminal dribbling Acute urinary retention
3 Voiding Problems Frequency Nocturia Urgency Urge incontinence
4 Older men 50
5 Etiology Benign Prostatic obstruction Detrusor Instability Detrusor Underactivity Neurogenic bladder
6 Exclusion criteria Less than 50 years of age Prostate cancer Previous invasive treatment for BPO Poorly controlled diabetes and diabetic neuropathy
7 Exclusion criteria History or physical examination suggestive of neurological disorder Pelvic surgery or trauma Sexually transmitted disease Use of drugs which have potential effects on bladder
8 Anatomy
9 Benign Prostatic Hyperplasia
10 Benign prostatic hyperplasia Benign prostatic enlargement Benign prostatic obstruction
11 Pathophysiology
12
13
14 Clinical studies in USA, Canada, Europe, Scotland, Netherlands, France, Germany and Japan suggested that Mild urinary symptoms are very common among man over 50 Mild symptoms are associated with little bother Moderate and severe symptoms are associated with increasing inconvenience and interference with living activities
15 Clinical studies in USA, Canada, Europe, Scotland, Netherlands, France, Germany and Japan suggested that The correlation between symptoms, prostate size and urinary flow rate is relatively low. BPH is a progressive disease as shown by Decrease in maximum flow rate Increase in residue volume Increase in prostate size Deterioration in symptom score
16 Risk factors Developing the disease Age Hormonal status Isaacs Jt. Prostate 1989
17 Risk Factors Surgical treatment increases with age and the degree of clinical symptoms at baseline. Nocturia and change in urinary stream seem to be the most important predictive symptoms
18 Diagnostic Work-up of Men Presenting with LUTS suggestive of Benign Prostatic Obstruction
19 Diagnostic tests have been classified as Mandatory: This test should be done in every patient Recommended: this test is of proven value in the evaluation of most patients and is strongly encouraged during initial evaluation Optional: this test is of proven value in selected patient and done at the discretion of the clinician Not recommended: there is no evidence to support the use of this test
20 Mandatory tests
21 History Nature, duration Previous surgical procedures General health issues Patient fitness
22 Quantification of Symptoms Symptom score 0-7 mild 8-19 moderate severe Quality of life Assessment
23
24 Physical Examination and Digital Rectal Examination Focused Examination on 1. Bladder distension 2. Hernia 3. Phimosis 4. Anal tone 5. Prostatic abnormalities 6. Motor and sensory function
25 Recommended Diagnostic tests Urinalysis Serum creatinine Serum Prostatic Specific Antigen 1. Cancer, BPH, infection, trauma, age, race may influence PSA 2. Level of PSA correlates with volume of prostate gland 3. Probability of prostate cancer correlates with PSA level 4. Test recommended because it may change the therapeutic option
26 Probability of prostate cancer among men with normal DRE. Adapted from Barry. PSA (ng/ml) Not known > 10.0 > 50 Probability of prostate cancer (%) PSA = prostate-specific specific antigen
27 Recommended Tests Flow Rate Recording Maximum urinary flow rate is the best single measure (Q max) At least two Q max, both with a volume >150ml voided volume Residue Urine Transabdominal Ultrasonography Voiding Diary
28 Flow rate and post void residue 尿流率測定及殘餘尿
29 Predictive ability of Qmax for a voided volume of 150ml or more Flow rate ml/ s Number Pressure flows Obstructed Not obstructed < (38%) 119 (89%) 16 (12%) 10 to (37%) 92 (71%) 38 (29%) >15 91 (26%) 44 (48%) 47 (52%) Total 356 (100%) AG number = pdet, qmax-2qmax 255 (71%) 101 (28%)
30 Voiding diary 泌尿日誌
31 Optional Tests Pressure flow studies prior to surgical treatment 1. Younger men <50 2. Elderly patient >80 3. Post void residue urine >300ml 4. Qmax >15ml/s 5. Suspicion of neurogenic bladder dysfunction 6. After radical pelvic surgery 7. Previous unsuccessful invasive treatment
32 Urodynamics Study 尿流動力學檢查
33 Cystometrogram 膀胱壓力容積曲線
34 Cystometrogram 膀胱壓力容積線
35 Cystometrogram 膀胱壓力容積線
36 Optional Tests Ultrasound image of prostate 1. Only recommended in selected patient 2. Usually done with random sextant biopsies to rule out prostate cancer
37 Optional Tests Imaging of upper urinary tract (USG or IVU) 1. Not recommended in uncomplicated benign prostate obstruction 2. Recommended in patient with upper urinary tract infection, hematuria, urolithiasis and renal insufficiency
38 Cystoscopy 膀胱尿道鏡檢查
39 Optional Tests Diagnostic cystoscopy 1. Not recommended because benefits do not outweigh the harm of the invasive study 2. Recommended at the time of surgical intervention
40 Tests Not Recommended Retrograde urethrogram Urethral pressure profilometry Voiding cystourethrography Electromyography
41 Video-Cystourethrography 動態放射學檢查
42 Video-Cystourethrography 動態放射學檢查
43 Management strategy Imperative indications for surgical intervention 1. Refractory urinary retention 2. Recurrent bleeding prostate 3. Renal failure 4. Bladder stones 5. Recurrent urinary tract infection 6. Large bladder diverticula
44 Management strategy Watchful waiting if no imperative indications for surgery and symptoms not bothersome Shared decision if symptoms bothersome Pressure flow studies when Qmax >10ml/s and interventional therapy is considered
45 Treatment
46 Watchful waiting 1. Mild to moderate uncomplicated LUTS which do not bother the patient 2. Yearly reassessment of symptom score, bothersome, flow rates and post-void residue
47 Medical Therapy 1. Regular follow up for progress, adverse events and alternate treatment 2. Yearly reassessment if stable
48 Adrenergic Receptor Antagonistic Acceptable option in patients Symptoms improved by 30-40% Flow rate improved by 16-25% No significant relief of obstruction Treatment should be discontinued if no improvement in symptoms after an 8-week trial
49 α Adrenergic Receptor Antagonistic All α blockers can cause dizziness, headaches, asthenia, orthostatic hypotension, drowsiness, nasal congestion and retrograde ejaculation Patient should be informed about the side effects and the need for long term use Efficacy of all contemporary agents is similar though the side-effect profiles might be different
50 5 α reductase inhibitor Acceptable treatment in patient with clinically enlarged prostates and bothersome symptoms only Capable of reducing prostate volume 20-30%, improving symptom scores 15% and flow rates ml/s Maximum benefits at 6 months Can alter the natural history of symptomatic BPH Side effects are diminished ejaculation, diminished libido and impotence Affect the PSA serum level
51 Phytotherapeutic agents Mode of action unknown Biological effect unclear Encouraging results in some clinical trials
52 Surgical management
53 Indications Refractory urinary retention Recurrent urinary tract infection Recurrent bleeding prostate Bladder stone Large bladder diverticulum Renal Failure
54 Choice of surgical treatment Transurethral bladder neck incision Transurethral resection of prostate Open prostatectomy Transurethral vaporization of prostate
55
56 Transurethral Resection of Prostate 經尿道前列線切除術
57 Transurethral Bladder Neck Incision 經尿道膀胱頸切開術
58 Outcome TURP mean increase Qmax 115% (+9.7ml/s) range ml/s TUBNI 100% (+7.8ml/s) range ml/s Open prostatectomy range ml/s All have a reduction of post void residue >50%
59 Complications Mortality <0.25% TUR syndrome 2% Blood transfusion 2--5% Stress Incontinence TUBNI 1.8%, TURP 2.2%, Open Prostatectomy 10% and TUVP 5%
60 Complications Bladder neck contracture and urethral stricture 1.8%, 4% and 0.4% after open prostatectomy, TURP and TUBNI 2.6%, 3.8% and 0.4% for open prostatectomy, TURP and TUBNI respectively
61 Complications Retrograde ejaculation Open Prostatectomy 80% TURP 65-70% TUBNI 40% Retreatment rate 1-2% per year for TURP,TUBNI and prostatectomy
62 Other Interventional Therapies Urethral stents Thermotherapy >45ºC Transurethral Microwave Thermotherapy Transurethral Needle Ablation Laser-coagulation Technique High Intensity Focused Ultrasound Balloon dilation Hyperthermia <45ºC
63
64
65
66
67
68 Recommendations for Treatment 1. Watchful waiting for patients with mild symptoms that have minimal or no impact on their life 2. Αlph-ablocker is a treatment option for patients with bothersome LUTS and no absolute indication for surgery 3. Surgical treatment is the first line treatment for patients with an absolute indication for treatment of LUTS 4. ILC with significant post operative morbidity and disappointing long term data is not recommended as a first line treatment
69 Recommendations for Treatment 5. Holmiun Laser resection of prostate is promising new technique 6. Transrectal High Intensity Focused Ultrasound is still investigational 7. TUNA is not recommended as first line therapy due to significant treatment failure rate 8. Transurethral microwave therapy should be reserved for patients who refused surgery
70 Follow up Watchful waiting First follow up at 6 months and then annually with IPSS and uroflowmetry 5-α reductase inhibitors Initial 12 weeks, 6 months and then annually with IPSS and uroflowmetry
71 Follow up Surgical management First postoperative visit at 6 weeks, then 6 months and then annually with histology, IPSS and uroflowmetry Alternative therapies First postoperative visit at 6 weeks, then at 3 months, 6 months and then annually with IPSS and uroflowmetry
72 Methodology 800 copies of questionnaire, a local Chinese translation of the World Health Organization approved International Prostate Symptom Score were distributed to men over 60 from 4 community centers in Hong Kong in August 1995
73 Prevalence 42 of male over 60 have moderate to severe urinary symptoms
74 Conclusion men in Hong Kong over 60 are suffering from moderate to severe urinary symptoms IN SILENCE and have moderate and severe symptoms respectively.
75 Conclusion These amount to 24% and 18% of the total male population over 60 Symptoms may be taken as a matter of aging Ignorance of availability of treatment Public education
76 Local Data From 01/10/2000 to 31/9/2001 Acute Urinary Retention Lower Urinary Tract Symptoms No. of patients Total 395
77 Distribution of patients Profile of patients with TURP done from 1 st January to 31 st December, 2001 Refracto ry ARU (averag e age of patients) ARU with proven BOO (average age of patients) LUTS with proven BOO (average age of patients) LUTS (average age of patients) BNS Bleeding CaP Grand Total With DM 2 (67) 4 (77.5) 6 (70.5) 0 Without DM 33 (74.3) 10 (76) 31 (70.1) 31 (68.5) Total 35 (73.9) 14 (76.4) 37 (70.6) 31 (68.5)
78 Average Qmax, voided volume and post void residue of LUTS patients before surgery were 7.8mL/s, 219mL and 123.3mL
79 Post Void Residue Volume There was a mean reduction of post-void residue of 72%
80 Treatment outcome The mean increase of Qmax following TURP for LUTS was +138% (range -22.7% to +587%) in absolute terms +9.7mL/s (range -2.3 to +39.9) The mean increase of Qmax for acute urinary retention was +15.2mL/s (range +1.3 to +38.7mL/s)
81 Complications There was no mortality The need for transfusion was 3 out of 109 (2.75%) No patients developed TUR-syndrome
82 Long term complications None of the patients became incontinence at the end of one year after surgery
83 Bladder neck contracture and urethral stricture The incidence of bladder contracture and urethral structure was 3 out of 109 (2.75%).
84 Hospital Stay The median hospital stay was 3 days
85 Conclusion TURP remains the surgical standard to which other interventional therapies are compared A pathology specimen is always available TURP is clearly durable Surgical techniques that remove obstructing tissue provide the greatest relief of both symptoms and urodynamic obstruction for patients with moderate to severe symptoms The interval to relief of symptoms, length of catheterization and re-catheterization rates are shorter with surgical than thermotherapy techniques
86
MANAGING BENIGN PROSTATIC HYPERTROPHY IN PRIMARY CARE DR GEORGE G MATHEW CONSULTANT FAMILY PHYSICIAN FELLOW IN SEXUAL & REPRODUCTIVE HEALTH
MANAGING BENIGN PROSTATIC HYPERTROPHY IN PRIMARY CARE DR GEORGE G MATHEW CONSULTANT FAMILY PHYSICIAN FELLOW IN SEXUAL & REPRODUCTIVE HEALTH INTRODUCTION (1) Part of male sexual reproductive organ Size
More informationEAU GUIDELINES POCKET EDITION 3
EAU GUIDELINES POCKET EDITION 3 CONTENTS: BENIGN PROSTATIC HYPERPLASIA URINARY INCONTINENCE UROLITHIASIS 2 3 EAU POCKET GUIDELINES POCKET EDITION 3 This is one of a series of convenient pocket size books
More informationGUIDELINES ON NON-NEUROGENIC MALE LUTS INCLUDING BENIGN PROSTATIC OBSTRUCTION (BPO)
GUIDELINES ON NON-NEUROGENIC MLE LUTS INCLUDING BENIGN PROSTTIC OBSTRUCTION (BPO) (Text update pril 2014) S. Gravas (chair),. Bachmann,. Descazeaud, M. Drake, C. Gratzke, S. Madersbacher, C. Mamoulakis,
More informationBenign Prostatic Hyperplasia (BPH):
Benign Prostatic Hyperplasia (BPH): Evidence Based Guidelines for Primary Care Providers Jeanne Martin, DNP, ANP-BC Objectives 1. Understand the pathophysiology and prevalence of BPH 2. Select the appropriate
More informationManagement of LUTS after TURP and MIT
Management of LUTS after TURP and MIT Hong Sup Kim Konkuk University TURP & MIT TURP : Gold standard MIT TUIP TUNA TUMT HIFU LASER Nd:YAG, ILC, HoLRP, KTP LUTS after TURP and MIT Improved : about 70% Persistent
More informationOverview. Urology Dine and Learn: Erectile Dysfunction & Benign Prostatic Hyperplasia. Iain McAuley September 15, 2014
Urology Dine and Learn: Erectile Dysfunction & Benign Prostatic Hyperplasia Iain McAuley September 15, 2014 Overview Review of the most recent guidelines for ED and BPH ED Guidelines CUA 2006 AUA 2011
More informationGUIDELINES ON NON-NEUROGENIC MALE LUTS INCLUDING BENIGN PROSTATIC OBSTRUCTION
GUIDELINES ON NON-NEUROGENIC MLE LUTS INCLUDING BENIGN PROSTTIC OBSTRUCTION (Text update March 2015) S. Gravas (Chair), T. Bach,. Bachmann, M. Drake, M. Gacci, C. Gratzke, S. Madersbacher, C. Mamoulakis,
More informationEAU GUIDELINES ON NON- NEUROGENIC MALE LUTS INCLUDING BENIGN PROSTATIC OBSTRUCTION
EAU GUIDELINES ON NON- NEUROGENIC MALE LUTS INCLUDING BENIGN PROSTATIC OBSTRUCTION (Text update March 2017) S. Gravas (Chair), T. Bach, M. Drake, M. Gacci, C. Gratzke, T.R.W. Herrmann, S. Madersbacher,
More informationThe Enlarged Prostate Symptoms, Diagnosis and Treatment
The Enlarged Prostate Symptoms, Diagnosis and Treatment MAC00031-01 Rev G Financial support for this seminar has been provided by NeoTract, Inc., the manufacturer of the UroLift System. 1 Today s Agenda
More informationEAU GUIDELINES ON NON- NEUROGENIC MALE LUTS INCLUDING BENIGN PROSTATIC OBSTRUCTION
EAU GUIDELINES ON NON- NEUROGENIC MALE LUTS INCLUDING BENIGN PROSTATIC OBSTRUCTION (Limited text update March 2016) S. Gravas (Chair), T. Bach, A. Bachmann, M. Drake, M. Gacci, C. Gratzke, S. Madersbacher,
More informationLower Urinary Tract Symptoms (LUTS) and Nurse-Led Clinics. Sean Diver Urology Advanced Nurse Practitioner candidate Letterkenny University Hospital
Lower Urinary Tract Symptoms (LUTS) and Nurse-Led Clinics Sean Diver Urology Advanced Nurse Practitioner candidate Letterkenny University Hospital 01/02/2018 Lower Urinary Tract Symptoms LUTS - one of
More informationVictoria Sharp, MD, MBA, FAAFP. Clinical Professor of Urology and Family Medicine
Victoria Sharp, MD, MBA, FAAFP Clinical Professor of Urology and Family Medicine Victoria Sharp, MD, MBA, FAAFP Market Chief Medial Officer AmeriHealth Caritas Family of Companies Office phone: (515) 330-3740
More informationIndex. urologic.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Ablative therapies, transurethral needle ablation, Adverse events, sexual side effects of BPH Aging, and incidence of BPH associated with
More informationDiagnostic approach to LUTS in men. Prof Dato Dr. Zulkifli Md Zainuddin Consultant Urologist / Head Of Urology Unit UKM Medical Center
Diagnostic approach to LUTS in men Prof Dato Dr. Zulkifli Md Zainuddin Consultant Urologist / Head Of Urology Unit UKM Medical Center Classification of LUTS Storage symptoms Voiding symptoms Post micturition
More informationPROSTATIC EMBOLIZATION FOR BENIGN HYPERPLASIA
St. Louis Hospital PROSTATIC EMBOLIZATION FOR BENIGN HYPERPLASIA INITIAL CLINICAL RESULTS Faculty of Medical Sciences New University of Lisbon JOÃO PISCO LUÍS CAMPOS PINHEIRO TIAGO BILHIM HUGO RIO TINTO
More informationMODULE 3: BENIGN PROSTATIC HYPERTROPHY
MODULE 3: BENIGN PROSTATIC HYPERTROPHY KEYWORDS: Prostatic hypertrophy, prostatic hyperplasia, PSA, voiding dysfunction, lower urinary tract symptoms (LUTS) At the end of this clerkship, the medical student
More informationIndex. urologic.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Ablation, of prostate, holmium laser, 485 495 African prune tree (Pygeum africanum), 454 455 Alfuzosin, 445 446 Alpha-adrenergic agonists,
More informationWhat should we consider before surgery? BPH with bladder dysfunction. Inje University Sanggye Paik Hospital Sung Luck Hee
What should we consider before surgery? BPH with bladder dysfunction Inje University Sanggye Paik Hospital Sung Luck Hee Diagnostic tests in three categories Recommendation: there is evidence to support
More informationOffice Management of Benign Prostatic Enlargement
Focus on CME at McGill University Office Management of Benign Prostatic Enlargement Symptomatic benign prostate enlargement is a common medical problem encountered in our aging society. Watchful waiting,
More information50% of men. 90% of men PATIENT FACTSHEET: BPH CONDITION AND TREATMENTS. Want more information? What are the symptoms?
PATIENT FACTSHEET: BPH CONDITION AND TREATMENTS What is Benign Prostatic Hyperplasia (enlarged prostate)? Benign prostatic hyperplasia (BPH) is a noncancerous enlargement of the prostate, the gland that
More informationBenign Prostatic Hyperplasia (BPH)
Benign Prostatic Hyperplasia (BPH) Definition Prostate gland enlargement is a common condition as men get older. Also called benign prostatic hyperplasia (BPH), prostate gland enlargement can cause bothersome
More informationNeurogenic bladder. Neurogenic bladder is a type of dysfunction of the bladder due to neurological disorder.
Definition: Neurogenic bladder Neurogenic bladder is a type of dysfunction of the bladder due to neurological disorder. Types: Nervous system diseases: Congenital: like myelodysplasia like meningocele.
More informationBenign Prostatic Hyperplasia. Jay Lee, MD, FRCSC Clinical Associate Professor University of Calgary
Benign Prostatic Hyperplasia Jay Lee, MD, FRCSC Clinical Associate Professor University of Calgary Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied,
More informationWhat is Benign Prostatic Hyperplasia (BPH)?
What is Benign Prostatic Hyperplasia (BPH)? Benign prostatic hyperplasia (BPH) is an enlarged prostate. The prostate goes through two main growth periods as a man ages. The first occurs early in puberty,
More informationAll about the Prostate
MEN S HEALTH Dr Nick Pendleton January 16 th 2018 All about the Prostate 1 What does it do? Functions of the Prostate 1. Secretes Prostatic Fluid slightly alkaline fluid, 30% of volume of seminal fluid,
More informationPROSTATIC ARTERY EMBOLISATION (PAE) FOR BENIGN PROSTATIC HYPERPLASIA. A Minimally Invasive Innovative Treatment
PROSTATIC ARTERY EMBOLISATION (PAE) FOR BENIGN PROSTATIC HYPERPLASIA A Minimally Invasive Innovative Treatment What is the prostate? The prostate is an accessory organ of the male reproductive system.
More informationBenign Prostatic Hyperplasia. Management of Benign Prostatic Hyperplasia. Goals of Therapy
Benign Prostatic Hyperplasia Management of Benign Prostatic Hyperplasia Goals of Therapy Improve or abolish lower urinary tract symptoms (LUTS) Prevent or delay clinical progression of benign prostatic
More informationChapter 4: Research and Future Directions
Chapter 4: Research and Future Directions Introduction Many of the future research needs listed in the 1994 Agency for Health Care Policy and Research (AHCPR) clinical practice guideline Benign Prostatic
More informationOriginal Policy Date
MP 7.01.39 Transurethral Microwave Thermotherapy Medical Policy Section Surgery Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013 Return to Medical
More informationNOTE: This policy is not effective until April 1, Transurethral Water Vapor Thermal Therapy of the Prostate
NOTE: This policy is not effective until April 1, 2019. Medical Policy Manual Surgery, Policy No. 210 Transurethral Water Vapor Thermal Therapy of the Prostate Next Review: December 2019 Last Review: December
More informationLower Urinary Tract Symptoms K Kuruvilla Zachariah Associate Specialist
Lower Urinary Tract Symptoms K Kuruvilla Zachariah Associate Specialist Lower Urinary Tract Symptoms Storage Symptoms Frequency, urgency, incontinence, Nocturia Voiding Symptoms Hesitancy, poor flow, intermittency,
More informationManagement of LUTS. Simon Woodhams February 2012
Management of LUTS Simon Woodhams February 2012 The management of lower urinary tract symptoms (LUTS) in men Implementing NICE guidance May 2010 NICE clinical guideline 97 Background Lower urinary tract
More informationExecutive Summary. Non-drug local procedures for treatment of benign prostatic hyperplasia 1. IQWiG Reports - Commission No.
IQWiG Reports - Commission No. N04-01 Non-drug local procedures for treatment of benign prostatic hyperplasia 1 Executive Summary 1 Translation of the executive summary of the final report Nichtmedikamentöse
More informationMini-Invasive Treatment in Urological Diseases Dott. Alberto Saita Responsabile Endourologia Istituto Clinico Humanitas - Rozzano
Dipartimento di Urologia Direttore Prof. Giorgio Guazzoni Mini-Invasive Treatment in Urological Diseases Dott. Alberto Saita Responsabile Endourologia Istituto Clinico Humanitas - Rozzano alberto.saita@humanitas.it
More informationDiagnosis and Mangement of Nocturia in Adults
Diagnosis and Mangement of Nocturia in Adults Christopher Chapple Professor of Urology Sheffield Teaching Hospitals University of Sheffield Sheffield Hallam University UK 23 rd October 2015 Terminology
More informationProstate Artery Embolization
Prostate Artery Embolization in the office interventional suite Robert J. Kennedy, M.D. Interventional & Vascular Center Melbourne, Florida The speaker has no financial conflicts of interest to disclose.
More informationLUTS after TURP: How come and how to manage? Matthias Oelke
LUTS after TURP: How come and how to manage? Matthias Oelke Department of Urology Global Congress on LUTD, Rome, 26 th June 2015 Disclosures Consultant, speaker, trial participant and/or research grants
More informationRezūm procedure for the Prostate
Rezūm procedure for the Prostate Mr Jas Kalsi Consultant Urological Surgeon This booklet has been provided to help answer the questions you may have with regards to your enlarged prostate and the Rezūm
More informationConsensus Meeting for Asian-Pacific BPH Guideline
Consensus Meeting for Asian-Pacific BPH Guideline Byung Ha Chung Yonsei University Health System S a t e l l i t e S y m p o s i u m I Contents Diagnosis and Treatment Guidelines for BPH Prostate Volume
More informationProstate Disease. Chad Baxter, MD
Prostate Disease Chad Baxter, MD Managing BPH and LUTS Chad Baxter, MD Department of Urology cbaxter@mednet.ucla.edu 33 nd Annual UCLA Intensive Course in Geriatric Medicine & Board Review Prevalence of
More informationProstate gland disorder พ.ต.ต.นพ.ส ร ต ก ตต ศ ภพร นพ.(สบ.2) โรงพยาบาลต ารวจ ส าน กงานต ารวจแห งชาต
Prostate gland disorder พ.ต.ต.นพ.ส ร ต ก ตต ศ ภพร นพ.(สบ.2) โรงพยาบาลต ารวจ ส าน กงานต ารวจแห งชาต Prostate cancer Overview Diagnosis Treatment Lower urinary tract symptoms EPIDEMIOLOGY The most common
More informationURODYNAMICS IN MALE LUTS: NECESSARY OR WASTE OF TIME?
URODYNAMICS IN MALE LUTS: NECESSARY OR WASTE OF TIME? Andrea Tubaro, MD, FEBU Chairman Department of Urology Sant Andrea Hospital Sapienza University of Rome, Italy Disclosures Consultant, paid speaker,
More informationLUTS A plea for a holistic approach. HUBERT GALLAGHER, MCh; FRCSI, FRCSI(Urol) Head of Urology Beacon Hospital
LUTS A plea for a holistic approach. HUBERT GALLAGHER, MCh; FRCSI, FRCSI(Urol) Head of Urology Beacon Hospital LUTS- Classification Men LUTS can be divided into: Storage Voiding Frequency Nocturia Urgency
More informationAmbulatory Try off Catheter (ATOC) Program for the Patient with Acute Retention of Urine Outpatient Service
Ambulatory Try off Catheter (ATOC) Program for the Patient with Acute Retention of Urine Outpatient Service Mr. Tang, Chi Chiu Kevin (APN) Urology Center Department of Surgery Kwong Wah Hospital Redevelopment
More informationProstate Health PHARMACIST VIEW
Prostate Health PHARMACIST VIEW Prostate Definition Prostate is a gland made of fibromuscular tissue. It is about 4 cm and surrounds the neck of the bladder and the urethra. It produces seminal fluid.
More informationMedifocus, Inc. OTCQB: MDFZF TSXV: MFS
Medifocus, Inc. OTCQB: MDFZF TSXV: MFS www.medifocusinc.com A Leader in Focused Heat Thermotherapy for the Treatment of Benign Prostatic Hyperplasia and Breast Cancer Except for historical information,
More informationVOIDING DYSFUNCTION IN ELDERLY MALE CURRENT STATUS
VOIDING DYSFUNCTION IN ELDERLY MALE CURRENT STATUS DR. FRANCIS LEE Voiding dysfunction Storage Emptying Common voiding dysfunction in elderly male Emptying BPH Storage Incontinence Overactive bladder Post-prostatectomy
More informationOveractive Bladder: Diagnosis and Approaches to Treatment
Overactive Bladder: Diagnosis and Approaches to Treatment A Hidden Condition* Many Many patients self-manage by voiding frequently, reducing fluid intake, and wearing pads Nearly Nearly two-thirds thirds
More informationP ROLIEVE. Thermodilatation System. The Prolieve System Patient Information is Directed to You, the Patient. A Transurethral Microwave Therapy Device
P ROLIEVE Thermodilatation System A Transurethral Microwave Therapy Device The Prolieve System Patient Information is Directed to You, the Patient. Contents Why am I being treated with the Prolieve Thermodilatation
More informationEarly-Stage Clinical Experiences of Holmium Laser Enucleation of the Prostate (HoLEP)
JRural Med 2007 ; 2 : 93 97 Original article Early-Stage Clinical Experiences of Holmium Laser Enucleation of the Prostate (HoLEP) Shuzo Hamamoto 1,TakehikoOkamura 1,HideyukiKamisawa 1,KentaroMizuno 1,
More informationInitial Experience of High Power Diode Laser for Vaporization of Prostate Muhammad Rafiq Zaki, Mujahid Hussain, Tahir Mehmood, Murtaza Hiraj
Original Article Initial Experience of High Power Diode Laser for Vaporization of Prostate Muhammad Rafiq Zaki, Mujahid Hussain, Tahir Mehmood, Murtaza Hiraj Abstract Objectives: Prospective evaluation
More informationCanadian Undergraduate Urology Curriculum (CanUUC): Prostate Diseases
Canadian Undergraduate Urology Curriculum (CanUUC): Prostate Diseases LUTS/Benign Prostate Hyperplasia Objectives 1. List the lower urinary tract symptoms (LUTS) found in men with BPH. 2. List the differential
More informationCase studies: LUTS. Case 1 history. Case 1 - questions. Case 1 - outcome. Case 2 - history. Case 1 learning point 14/07/2015 DR JON REES
Case 1 history Case studies: LUTS DR JON REES A 49 year old male comes to see you he has had gradual deterioration of his flow over the last few years- he saw a colleague of yours 6 weeks ago who recorded
More informationThe Egyptian Journal of Hospital Medicine (January 2019) Vol. 74 (6), Page
The Egyptian Journal of Hospital Medicine (January 2019) Vol. 74 (6), Page 1377-1386 Evaluation of Silodosin in Comparison to Tamuslosin in Treatment of Benign Prostatic Hyperplasia with lower Urinary
More informationSaving. Kidneys. Benign Prostate Disease
Saving Kidneys 9 Benign Prostate Disease This booklet will tell you more about the prostate gland. Its functions and benign hyperplasia have been defined in a simple way. Ways to prevent and treat this
More informationSurgical Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA GUIDELINE
1 Approved by the AUA Board of Directors May 2018 Authors disclosure of potential conflicts of interest and author/staff contributions appear at the end of the article. 2018 by the American Urological
More informationMale Lower Urinary Tract Symptoms: Management in primary care and beyond. Daniel Cohen PhD FRCS(Urol) Consultant Urological Surgeon
Male Lower Urinary Tract Symptoms: Management in primary care and beyond Daniel Cohen PhD FRCS(Urol) Consultant Urological Surgeon 1 LUTS Very common: 1/3 men over age of 50 have moderate to severe LUTS
More informationRELATIONSHIPS BETWEEN AMERICAN UROLOGICAL ASSOCIATION SYMPTOM INDEX, PROSTATE VOLUME, PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA
American Urological Association symptom index for BPH RELATIONSHIPS BETWEEN AMERICAN UROLOGICAL ASSOCIATION SYMPTOM INDEX, PROSTATE VOLUME, AND DISEASE-SPECIFIC QUALITY OF LIFE QUESTION IN PATIENTS WITH
More informationShrestha A, Chalise PR, Sharma UK, Gyawali PR, Shrestha GK, Joshi BR. Department of Surgery, TU Teaching Hospital, Maharajgunj, Kathmandu, Nepal
Original Article Intravesical Prostatic Protrusion is better than Prostate Volume in Predicting Symptom Severity in Benign Prostatic Hyperplasia: A Prospective Clinical Study Shrestha A, Chalise PR, Sharma
More informationNON-Neurogenic Chronic Urinary Retention AUA White Paper
NON-Neurogenic Chronic Urinary Retention AUA White Paper Great Lakes SUNA Inside Urology March 16, 2018 Michelle J. Lajiness FNP-BC Nurse Practitioner DMC Urology Incidence Really unknown Lack consensus
More informationIncreasing Awareness, Diagnosis, and Treatment of BPH, LUTS, and EP
Introduction to Enlarged Prostate E. David Crawford, MD Professor of Surgery (Urology) and Radiation Oncology Head, Urologic Oncology E. David Crawford Endowed Chair in Urologic Oncology University of
More informationPRABHAKAR SINGH*, MANOJ INDURKAR, AMITA SINGH, PALLAVI INDURKAR
Academic Sciences International Journal of Current Pharmaceutical Research ISSN- 0975-7066 Vol 5, Issue 1, 2013 Research Article COMPARISON OF THE EFFICACY AND SAFETY OF TAMSULOSIN (0.4 V/S (and) FINASTERIDE
More informationHong Kong College of Surgical Nursing
Hong Kong College of Surgical Nursing Higher Surgical Nursing Training: Part B Specialty - Urological Nursing Curriculum TABLE OF CONTENTS No. Contents Page. Introduction. Aims. Learning Objectives 4.
More informationEvaluation and Treatment of Lower Urinary Tract Symptoms in Older Men
Evaluation and Treatment of Lower Urinary Tract Symptoms in Older Men P. Abrams,*, C. Chapple, S. Khoury, C. Roehrborn and J. de la Rosette on behalf of the International Scientific Committee and members
More informationThe potential for NX-1207 in benign prostatic hyperplasia: an update for clinicians
Therapeutic Advances in Chronic Disease Review The potential for NX-1207 in benign prostatic hyperplasia: an update for clinicians Neal Shore and Barrett Cowan Ther Adv Chronic Dis (2011) 2(6) 377 383
More informationOVER 70% OF MEN IN THEIR 60s HAVE SYMPTOMS OF BPH 1
PATIENT INFORMATION BPH affects more than 500 million men worldwide, with many men suffering from symptoms of enlarged prostate. 1 You no longer have to be one of them! OVER 70% OF MEN IN THEIR 60s HAVE
More informationClinical guideline Published: 23 May 2010 nice.org.uk/guidance/cg97
Lower urinary tract symptoms in men: management Clinical guideline Published: 23 May 2010 nice.org.uk/guidance/cg97 NICE 2017. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationWhen to worry, when to test?
Focus on CME at the University of Calgary Prostate Cancer: When to worry, when to test? Bryan J. Donnelly, MSc, MCh, FRCSI, FRCSC Presented at a Canadian College of Family Practitioner s conference (October
More informationMale LUTS. Dr. Brian Ho. Division of Urology Department of Surgery Queen Mary Hospital
Male LUTS Dr. Brian Ho Division of Urology Department of Surgery Queen Mary Hospital Mr. Siu M/78 Known to have HT & DM since 2008 on follow up with General ut-patient Clinic (GPC) Noticed to have worsening
More informationChapter 2: Methodology
Chapter 2: Methodology TABLE OF CONTENTS Introduction... 2 Study Selection and Data Abstraction... 2 Data Synthesis... 8 Guideline Development and Approvals... 9 Conflict of Interest... 10 Copyright 2010
More informationGoals & Objectives by Year in Training: U-1
Goals & Objectives by Year in Training: U-1 U-1 (PGY-2, 3) Resident Responsibilities, Goals and Objectives In addition to the goals listed for PGY-1, the U-1 resident will add to his/her knowledge base
More informationWednesday 25 June Poster Session 9: BPH 1 Chairmen: M. Speakman and D. Rosario
Wednesday 25 June 14.30 15.30 Poster Session 9: BPH 1 Chairmen: M. Speakman and D. Rosario P080 Unreliable residual volume measurement after increased water load diuresis G. ALIVIZATOS, A. SKOLARIKOS,
More informationChapter 3: Results of the Treatment Outcomes Analyses
Chapter 3: Results of the Treatment Outcomes Analyses Introduction To determine the appropriateness of individual therapies, as well as to develop practice recommendations, the American Urological Association
More informationElements for a Public Summary
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Benign prostatic hyperplasia (BPH), also called benign prostatic hypertrophy or benign prostatic obstruction, is a condition in
More informationEFFICACY OF LASER SURGERY FOR BENIGN PROSTATIC HYPERPLASIA TREATMENT
EFFICACY OF LASER SURGERY FOR BENIGN PROSTATIC HYPERPLASIA TREATMENT Hasmeinda Medical faculty of Universitas Muhammadiyah Surakarta ABSTRACT Benign prostatic hyperplasia (BPH) is the most important cases
More informationVoiding Dysfunction Block lecture, 5 th year student. Choosak Pripatnanont, Department of Surgery, PSU.
Voiding Dysfunction 2009 Block lecture, 5 th year student. Choosak Pripatnanont, Department of Surgery, PSU. Objectives Understand and explain physiologic function and dysfunction of lower urinary tract.
More informationDOWNLOAD OR READ : TREATMENT OF BENIGN PROSTATIC HYPERPLASIA PDF EBOOK EPUB MOBI
DOWNLOAD OR READ : TREATMENT OF BENIGN PROSTATIC HYPERPLASIA PDF EBOOK EPUB MOBI Page 1 Page 2 treatment of benign prostatic hyperplasia treatment of benign prostatic pdf treatment of benign prostatic
More informationName of Policy: Transurethral Microwave Thermotherapy
Name of Policy: Transurethral Microwave Thermotherapy Policy #: 449 Latest Review Date: September 2013 Category: Surgery Policy Grade: B Background/Definitions: As a general rule, benefits are payable
More informationISSN: (Print) (Online) Journal homepage:
Archives of Andrology Journal of Reproductive Systems ISSN: 0148-5016 (Print) (Online) Journal homepage: http://www.tandfonline.com/loi/iaan19 CHANGE IN INTERNATIONAL PROSTATE SYMPTOM SCORE AFTER TRANSURETHRAL
More informationGENERAL GOALS & OBJECTIVES U-1. U-1 (PGY-2, 3) GENERAL GOALS and OBJECTIVES
GENERAL GOALS & OBJECTIVES U-1 U-1 (PGY-2, 3) GENERAL GOALS and OBJECTIVES In addition to the goals listed for PGY-1, the U-1 resident will add to his/her knowledge base by participating actively in conferences,
More informationBPH / LUTS. Prevalence. Prevalence of BPH. It is abnormal NOT to have benign growth of the prostate with increasing age. Prevalence.
BPH / LUTS Dr Jonny Coxon MA MD MRCS MRCGP DRCOG FECSM Beaconsfield Medical Practice, Brighton & Brighton & Sussex Universities NHS Trust As man draws near the common goal Can anything be sadder Than he
More informationLasers in Urology. Sae Woong Choi, Yong Sun Choi, Woong Jin Bae, Su Jin Kim, Hyuk Jin Cho, Sung Hoo Hong, Ji Youl Lee, Tae Kon Hwang, Sae Woong Kim
www.kjurology.org http://dx.doi.org/10.4111/kju.2011.52.12.824 Lasers in Urology 120 W Greenlight HPS Laser Photoselective Vaporization of the Prostate for Treatment of Benign Prostatic Hyperplasia in
More information4 th Year Urology Core Objectives Keith Rourke (Revised June 1, 2007)
4 th Year Urology Core Objectives Keith Rourke (Revised June 1, 2007) I. Genitourinary Trauma: 1. Goal: The student will be able to demonstrate a basic clinical approach to the management & diagnosis of
More informationMr. GIT KAH ANN. Pakar Klinikal Urologi Hospital Kuala Lumpur.
Mr. GIT KAH ANN Pakar Klinikal Urologi Hospital Kuala Lumpur drgitka@yahoo.com 25 Jan 2007 HIGHLIGHTS Introduction ICS Definition Making a Diagnosis Voiding Chart Investigation Urodynamics Ancillary Investigations
More informationEAU Guidelines on Management of Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO)
EAU Guidelines on Management of Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO) S. Gravas (Chair), J.N. Cornu, M.J. Drake, M. Gacci, C. Gratzke, T.R.W.
More informationSURGICAL MANAGEMENT OF BPH IN GHANA: A NEED TO IMPROVE ACCESS TO TRANSURETHRAL RESECTION OF THE PROSTATE
July 2012 East African Medical Journal 241 East African Medical Journal Vol. 89 No. 7 July 2012 SURGICAL MANAGEMENT OF BPH IN GHANA: A NEED TO IMPROVE ACCESS TO TRANSURETHRAL RESECTION OF THE PROSTATE
More informationManagement of Voiding Dysfunction after Prostate Radiotherapy
Management of Voiding Dysfunction after Prostate Radiotherapy Up to Date Symposium on Uro-Oncology December 7, 2012 Belo Horizonte, Brazil Jaspreet S. Sandhu, MD Department of Surgery/Urology Memorial
More informationAn Anteriorly Positioned Midline Prostatic Cyst Resulting in Lower Urinary Tract Symptoms
Case Report INJ 2010;14:125-129 An Anteriorly Positioned Midline Prostatic Cyst Resulting in Lower Urinary Tract Symptoms Joo-Yong Lee, Dong-Hyuk Kang, Hee-Young Park, Jung-Soo Park, Young-Woo Son, Hong-Sang
More informationUrinary Adverse Events after Radiation Therapy for Prostate Cancer
Urinary Adverse Events after Radiation Therapy for Prostate Cancer Sexual Medicine Society of North America Scottsdale, Arizona 2016 Jaspreet S. Sandhu, MD Department of Surgery/Urology Memorial Sloan
More informationTreating BPH: Comparing Rezum UroLift and HoLEP
Treating BPH: Comparing Rezum UroLift and HoLEP Scott M. Cheney MD Mayo Clinic Arizona 2018 MFMER slide-1 Welcome to AZ 2018 MFMER slide-2 Outline Background on BPH, Rezum, Urolift, HoLEP AUA Guideline
More informationTHE UROLOGY GROUP
THE UROLOGY GROUP www.urologygroupvirginia.com 1860 Town Center Drive Suite 150/160 Reston, VA 20190 703-480-0220 19415 Deerfield Avenue Suite 112 Leesburg, VA 20176 703-724-1195 224-D Cornwall Street,
More informationSome prostatic diseases
Some prostatic diseases Benign Prostatic Hyperplasia (Nodular Hyperplasia) Extremely common Present in a significant number of men by the age of 40 & its frequency rises progressively with age, reaching
More informationCan 80 W KTP Laser Vaporization Effectively Relieve the Obstruction in Benign Prostatic Hyperplasia?: A Nonrandomized Trial
pissn: 2287-428 / eissn: 2287-469 World J Mens Health 212 December 3(3): 16-165 http://dx.doi.org/1.5534/wjmh.212.3.3.16 Original Article Can 8 W KTP Laser Vaporization Effectively Relieve the Obstruction
More informationOriginal Article - Lasers in Urology. Min Ho Lee, Hee Jo Yang, Doo Sang Kim, Chang Ho Lee, Youn Soo Jeon
www.kjurology.org http://dx.doi.org/10.4111/kju.2014.55.11.737 Original Article - Lasers in Urology http://crossmark.crossref.org/dialog/?doi=10.4111/kju.2014.55.11.737&domain=pdf&date_stamp=2014-11-16
More informationKorean Urologist s View of Practice Patterns in Diagnosis and Management of Benign Prostatic Hyperplasia: A Nationwide Survey
Original Article DOI 10.3349/ymj.2010.51.2.248 pissn: 0513-5796, eissn: 1976-2437 Yonsei Med J 51(2):248-252, 2010 Korean Urologist s View of Practice Patterns in Diagnosis and Management of Benign Prostatic
More informationQuestions and Answers About the Prostate-Specific Antigen (PSA) Test
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Questions and Answers
More informationAUCKLAND REGIONAL UROLOGY GUIDELINES AND REFERRAL RECOMMENDATIONS
AUCKLAND REGIONAL UROLOGY GUIDELINES AND REFERRAL RECOMMENDATIONS This document outlines the urological conditions currently funded at Auckland District Health Board (ADHB), Counties Manukau District Health
More information